Maintenance immunotherapy and chemo after surgery for metastatic colon cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies tislelizumab plus capecitabine given after surgery to help prevent metastatic colorectal cancer from coming back. It may be an option if you recently had surgery that removed visible disease and you have good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 20 and 79 years old
- Have confirmed colorectal cancer by biopsy or test results
- Have had surgery for metastatic colorectal cancer and were considered “no evidence of disease” afterward
- Have had complete tumor removal (no visible remaining tumor), especially if cancer had spread to the belly lining
- Have not had any chemotherapy before
- Be able to do normal daily activities (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This study tests whether an immunotherapy drug called tislelizumab can help prevent colon cancer from coming back after surgery. It is for people with a specific genetic feature (dMMR) in their tumor, which may make the treatment more effective.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests whether giving an immunotherapy drug (tislelizumab) together with chemotherapy before and after surgery can improve outcomes for people with a specific type of colorectal cancer (MSI-high). The goal is to see if this treatment helps shrink the tumor and reduces the risk of cancer coming back.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
Hear when a new Metastatic Colorectal Cancer，NED trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.